Kowey P R, Friehling T D, Marinchak R A, Sulpizi A M, Stohler J L
Department of Medicine, Medical College of Pennsylvania, Philadelphia 19129.
Chest. 1988 Jan;93(1):54-9. doi: 10.1378/chest.93.1.54.
Amiodarone has been reported to be a remarkably safe and effective drug in the European and South American experience but American investigators have published conflicting data. Since this disparity may be explained by a different dosing schedule, we prospectively evaluated the safety and efficacy of a low dose regimen in a group of 68 patients with cardiac arrhythmia resistant to conventional therapy, of whom 57 had manifested either ventricular tachycardia or fibrillation. All were loaded either intravenously (17) or orally, and maintained on an oral dose of 200 to 600 mg/day (mean daily dose 317 +/- 114 mg) and followed for 4 to 58 months (22 +/- 11). Results indicated that amiodarone was a safe and effective antiarrhythmic drug when used in lower doses.
在欧洲和南美洲的经验中,胺碘酮据报道是一种非常安全有效的药物,但美国研究人员发表了相互矛盾的数据。由于这种差异可能由不同的给药方案来解释,我们前瞻性地评估了低剂量方案在一组68例对传统治疗耐药的心律失常患者中的安全性和有效性,其中57例表现为室性心动过速或颤动。所有患者均通过静脉注射(17例)或口服进行负荷给药,并维持口服剂量为200至600毫克/天(平均每日剂量317 +/- 114毫克),随访4至58个月(22 +/- 11)。结果表明,低剂量使用胺碘酮是一种安全有效的抗心律失常药物。